Interferon alfa-n1 (Wellferon)® in juvenile onset recurrent respiratory papillomatosis: Results of a randomized study in twelve collaborative institutions

B. Leventhal, H. Dedo, L. Gardiner, B. F. McCabe, M. Richardson, J. Whisnant, H. Kashima, K. Clark, D. Donovan, H. Goepfert, P. Mounts, G. Singleton, D. Wold, S. Cohen, B. Fearon, R. Lusk, H. Muntz, P. Weck, A. Yonkers

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Sixty-six patients with clinically severe juvenile-onset recurrent respiratory papillomatosis (KRP) were entered into a 12-month randomized crossover study to evaluate interferon alpha-nl WeUferon® (WFN) as an adjuvant to CO2 laser surgical excision. Eligibility required disease onset to he before age 16, and an endoscopic excision requirement of at least three operations in the 6 months immediately prior to entry. Patients were randomized to Observation versus WFN at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months. The patient groups were comparable in extent of disease at entry. Total extent of disease was determined by a composite score derived from the number of diseased anatomic sites and extent of surface area and lumen encroachment present at each site. Standard endoscopic excisions were performed every 2 months and clinical courses compared on a basis of composite scores determined at each endoscopy. Statistically significant improvement occurred in the patient group which received WFN. We conclude that interferon alpha n-1 is an effective adjuvant to surgery in RRP management.

Original languageEnglish (US)
Pages (from-to)334-340
Number of pages7
JournalLaryngoscope
Volume98
Issue number3
StatePublished - 1988
Externally publishedYes

Fingerprint

Interferon-alpha
Gas Lasers
Cross-Over Studies
Endoscopy
Observation
interferon alfa-n1
Recurrent respiratory papillomatosis

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Leventhal, B., Dedo, H., Gardiner, L., McCabe, B. F., Richardson, M., Whisnant, J., ... Yonkers, A. (1988). Interferon alfa-n1 (Wellferon)® in juvenile onset recurrent respiratory papillomatosis: Results of a randomized study in twelve collaborative institutions. Laryngoscope, 98(3), 334-340.

Interferon alfa-n1 (Wellferon)® in juvenile onset recurrent respiratory papillomatosis : Results of a randomized study in twelve collaborative institutions. / Leventhal, B.; Dedo, H.; Gardiner, L.; McCabe, B. F.; Richardson, M.; Whisnant, J.; Kashima, H.; Clark, K.; Donovan, D.; Goepfert, H.; Mounts, P.; Singleton, G.; Wold, D.; Cohen, S.; Fearon, B.; Lusk, R.; Muntz, H.; Weck, P.; Yonkers, A.

In: Laryngoscope, Vol. 98, No. 3, 1988, p. 334-340.

Research output: Contribution to journalArticle

Leventhal, B, Dedo, H, Gardiner, L, McCabe, BF, Richardson, M, Whisnant, J, Kashima, H, Clark, K, Donovan, D, Goepfert, H, Mounts, P, Singleton, G, Wold, D, Cohen, S, Fearon, B, Lusk, R, Muntz, H, Weck, P & Yonkers, A 1988, 'Interferon alfa-n1 (Wellferon)® in juvenile onset recurrent respiratory papillomatosis: Results of a randomized study in twelve collaborative institutions', Laryngoscope, vol. 98, no. 3, pp. 334-340.
Leventhal, B. ; Dedo, H. ; Gardiner, L. ; McCabe, B. F. ; Richardson, M. ; Whisnant, J. ; Kashima, H. ; Clark, K. ; Donovan, D. ; Goepfert, H. ; Mounts, P. ; Singleton, G. ; Wold, D. ; Cohen, S. ; Fearon, B. ; Lusk, R. ; Muntz, H. ; Weck, P. ; Yonkers, A. / Interferon alfa-n1 (Wellferon)® in juvenile onset recurrent respiratory papillomatosis : Results of a randomized study in twelve collaborative institutions. In: Laryngoscope. 1988 ; Vol. 98, No. 3. pp. 334-340.
@article{07e24caaccf44e9eabe122b5eac0f389,
title = "Interferon alfa-n1 (Wellferon){\circledR} in juvenile onset recurrent respiratory papillomatosis: Results of a randomized study in twelve collaborative institutions",
abstract = "Sixty-six patients with clinically severe juvenile-onset recurrent respiratory papillomatosis (KRP) were entered into a 12-month randomized crossover study to evaluate interferon alpha-nl WeUferon{\circledR} (WFN) as an adjuvant to CO2 laser surgical excision. Eligibility required disease onset to he before age 16, and an endoscopic excision requirement of at least three operations in the 6 months immediately prior to entry. Patients were randomized to Observation versus WFN at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months. The patient groups were comparable in extent of disease at entry. Total extent of disease was determined by a composite score derived from the number of diseased anatomic sites and extent of surface area and lumen encroachment present at each site. Standard endoscopic excisions were performed every 2 months and clinical courses compared on a basis of composite scores determined at each endoscopy. Statistically significant improvement occurred in the patient group which received WFN. We conclude that interferon alpha n-1 is an effective adjuvant to surgery in RRP management.",
author = "B. Leventhal and H. Dedo and L. Gardiner and McCabe, {B. F.} and M. Richardson and J. Whisnant and H. Kashima and K. Clark and D. Donovan and H. Goepfert and P. Mounts and G. Singleton and D. Wold and S. Cohen and B. Fearon and R. Lusk and H. Muntz and P. Weck and A. Yonkers",
year = "1988",
language = "English (US)",
volume = "98",
pages = "334--340",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Interferon alfa-n1 (Wellferon)® in juvenile onset recurrent respiratory papillomatosis

T2 - Results of a randomized study in twelve collaborative institutions

AU - Leventhal, B.

AU - Dedo, H.

AU - Gardiner, L.

AU - McCabe, B. F.

AU - Richardson, M.

AU - Whisnant, J.

AU - Kashima, H.

AU - Clark, K.

AU - Donovan, D.

AU - Goepfert, H.

AU - Mounts, P.

AU - Singleton, G.

AU - Wold, D.

AU - Cohen, S.

AU - Fearon, B.

AU - Lusk, R.

AU - Muntz, H.

AU - Weck, P.

AU - Yonkers, A.

PY - 1988

Y1 - 1988

N2 - Sixty-six patients with clinically severe juvenile-onset recurrent respiratory papillomatosis (KRP) were entered into a 12-month randomized crossover study to evaluate interferon alpha-nl WeUferon® (WFN) as an adjuvant to CO2 laser surgical excision. Eligibility required disease onset to he before age 16, and an endoscopic excision requirement of at least three operations in the 6 months immediately prior to entry. Patients were randomized to Observation versus WFN at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months. The patient groups were comparable in extent of disease at entry. Total extent of disease was determined by a composite score derived from the number of diseased anatomic sites and extent of surface area and lumen encroachment present at each site. Standard endoscopic excisions were performed every 2 months and clinical courses compared on a basis of composite scores determined at each endoscopy. Statistically significant improvement occurred in the patient group which received WFN. We conclude that interferon alpha n-1 is an effective adjuvant to surgery in RRP management.

AB - Sixty-six patients with clinically severe juvenile-onset recurrent respiratory papillomatosis (KRP) were entered into a 12-month randomized crossover study to evaluate interferon alpha-nl WeUferon® (WFN) as an adjuvant to CO2 laser surgical excision. Eligibility required disease onset to he before age 16, and an endoscopic excision requirement of at least three operations in the 6 months immediately prior to entry. Patients were randomized to Observation versus WFN at a dose of 5 MU/m2 daily for 28 days and three times weekly for 5 months. The patient groups were comparable in extent of disease at entry. Total extent of disease was determined by a composite score derived from the number of diseased anatomic sites and extent of surface area and lumen encroachment present at each site. Standard endoscopic excisions were performed every 2 months and clinical courses compared on a basis of composite scores determined at each endoscopy. Statistically significant improvement occurred in the patient group which received WFN. We conclude that interferon alpha n-1 is an effective adjuvant to surgery in RRP management.

UR - http://www.scopus.com/inward/record.url?scp=0023911486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023911486&partnerID=8YFLogxK

M3 - Article

C2 - 3278186

AN - SCOPUS:0023911486

VL - 98

SP - 334

EP - 340

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 3

ER -